ArticleFrontiers in oncology2019

Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC).

Pei-Wen Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.